Candel Therapeutics Q1 2026 net loss $8.9M; BLA submission for CAN-2409 on track for Q4 2026

Candel Therapeutics, Inc.

Net loss of $8.9M in Q1 2026 vs net income $7.4M in Q1 2025; R&D expense $9.8M.
Cash and equivalents $194.8M as of March 31, 2026, expected to fund operations into Q1 2028.
Plans to submit BLA for aglatimagene (CAN-2409) in localized prostate cancer in Q4 2026.
Extended follow-up from Phase 2a NSCLC trial shows 50% of patients survived >24 months; Phase 3 NSCLC trial to start June 2026.
Announced commercial partnership with EVERSANA and $100M royalty funding agreement with RTW for potential launch.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.